4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage genetic medicines company, has announced its participation in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference. The company's management will engage in a fireside chat and be available for one-on-one meetings during the event.
Key details of the presentation:
- Date: Thursday, August 15, 2024
- Time: 12:00 p.m. ET
A webcast of the presentation will be available, and an archived version will be accessible for up to one year on the company's investor relations website. This event provides an opportunity for 4DMT to showcase its progress in developing genetic medicines for large market diseases, particularly in the field of ophthalmology.
4D Molecular Therapeutics (Nasdaq: FDMT), un'azienda nel settore delle medicine genetiche in fase clinica, ha annunciato la sua partecipazione alla 4ª Conferenza Virtuale Annuale di Oftalmologia H.C. Wainwright. Il management dell'azienda parteciperà a una chiacchierata informale e sarà disponibile per incontri individuali durante l'evento.
Dettagli chiave della presentazione:
- Data: Giovedì, 15 Agosto 2024
- Ora: 12:00 p.m. ET
Un webcast della presentazione sarà disponibile e una versione archiviata sarà accessibile per un anno sul sito web delle relazioni con gli investitori dell'azienda. Questo evento offre a 4DMT l'opportunità di mostrare i suoi progressi nello sviluppo di medicine genetiche per malattie di largo mercato, in particolare nel campo dell'oftalmologia.
4D Molecular Therapeutics (Nasdaq: FDMT), una empresa de medicamentos genéticos en etapa clínica, ha anunciado su participación en la 4ª Conferencia Virtual Anual de Oftalmología de H.C. Wainwright. La dirección de la empresa participará en una charla informal y estará disponible para reuniones uno a uno durante el evento.
Detalles clave de la presentación:
- Fecha: Jueves, 15 de agosto de 2024
- Hora: 12:00 p.m. ET
Se ofrecerá una transmisión web de la presentación y una versión archivada estará accesible durante un año en el sitio web de relaciones con inversores de la empresa. Este evento brinda a 4DMT la oportunidad de mostrar sus avances en el desarrollo de medicamentos genéticos para enfermedades de gran mercado, especialmente en el campo de la oftalmología.
4D Molecular Therapeutics (Nasdaq: FDMT), 임상 단계의 유전자 치료 회사가 H.C. Wainwright 제4회 연례 안과 가상 회의에 참여한다고 발표했습니다. 회사의 경영진은 대담에 참여하고 행사 중 일대일 미팅을 진행할 예정입니다.
발표의 주요 세부 사항:
- 날짜: 2024년 8월 15일 목요일
- 시간: 오후 12:00 ET
발표의 웹캐스트가 제공되며, 아카이브된 버전은 회사의 투자자 관계 웹사이트에서 1년 동안 접근할 수 있습니다. 이 행사는 4DMT가 안과학 분야에서 특히 대규모 시장 질병을 위한 유전자 치료 개발의 진전을 선보일 수 있는 기회를 제공합니다.
4D Molecular Therapeutics (Nasdaq: FDMT), une entreprise de médicaments génétiques en phase clinique, a annoncé sa participation à la 4ème Conférence Virtuelle Annuelle d'Ophthalmologie H.C. Wainwright. La direction de l'entreprise participera à une discussion décontractée et sera disponible pour des réunions individuelles pendant l'événement.
Détails clés de la présentation :
- Date : Jeudi 15 août 2024
- Heure : 12h00 ET
Une diffusion en direct de la présentation sera disponible, et une version archivée sera accessible pendant un an sur le site Web des relations avec les investisseurs de l'entreprise. Cet événement offre à 4DMT l'occasion de mettre en avant ses progrès dans le développement de médicaments génétiques pour des maladies de grand marché, en particulier dans le domaine de l'ophtalmologie.
4D Molecular Therapeutics (Nasdaq: FDMT), ein Unternehmen im klinischen Stadium der gentherapeutischen Medikamente, hat seine Teilnahme an der 4. jährlichen virtuellen Augenheilkunde-Konferenz von H.C. Wainwright bekannt gegeben. Das Management des Unternehmens wird an einem informellen Gespräch teilnehmen und steht während der Veranstaltung für persönliche Treffen zur Verfügung.
Wichtige Details zur Präsentation:
- Datum: Donnerstag, 15. August 2024
- Zeit: 12:00 Uhr ET
Ein Webcast der Präsentation wird zur Verfügung stehen und eine archivierte Version wird für bis zu ein Jahr auf der Investor-Relations-Website des Unternehmens zugänglich sein. Diese Veranstaltung bietet 4DMT die Möglichkeit, seine Fortschritte bei der Entwicklung genetischer Arzneimittel für große Marktkrankheiten, insbesondere im Bereich der Augenheilkunde, zu präsentieren.
- None.
- None.
EMERYVILLE, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will participate in a fireside chat at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference. Members of the management team will also be available for one-on-one meetings.
H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
| Presentation Date: | Thursday, August 15, 2024 |
| Presentation Time: | 12:00 p.m. ET |
| Webcast Link: | Webcast |
An archived copy of the webcast will be available for up to one year by visiting the “Investors” section of the 4DMT website at https://ir.4dmoleculartherapeutics.com/events.
About 4DMT
4DMT is a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases in ophthalmology and pulmonology. 4DMT’s proprietary invention platform, Therapeutic Vector Evolution, combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences to invent customized and evolved vectors for use in our wholly owned and partnered product candidates. Our product design, development, and manufacturing engine helps us efficiently create and advance our diverse product pipeline with the goal of revolutionizing medicine with potential curative therapies for millions of patients. Currently, 4DMT is advancing six clinical-stage and one preclinical product candidate, each tailored to address rare and large market diseases in ophthalmology, pulmonology and cardiology. In addition, 4DMT is also advancing programs in CNS through a gene editing partnership. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.
All of our product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration (FDA) or any other regulatory authority. No representation is made as to the safety or effectiveness of our product candidates for the therapeutic uses for which they are being studied.
Learn more at www.4DMT.com and follow us on LinkedIn.
Contacts:
Media:
Katherine Smith
Inizio Evoke Comms
Katherine.Smith@inizioevoke.com
Investors:
Julian Pei
Head of Investor Relations and Corporate Finance
Investor.Relations@4DMT.com
FAQ
When is 4D Molecular Therapeutics (FDMT) presenting at the H.C. Wainwright Ophthalmology Conference?
Will there be a webcast of FDMT's presentation at the H.C. Wainwright conference?
What type of event is FDMT participating in at the H.C. Wainwright conference?
What is the focus of 4D Molecular Therapeutics (FDMT)?
